Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | SNCA | P37840 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.46 |
| ▸ | GAA | P10253 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24155698 | 0.80 | NPC1 (0.66) | SMN1; SMN2RAB9ANPC1MAPTKDM4E | |
| SCHEMBL24587106 | 0.79 | NPC1 (0.48) | SMN1; SMN2RAB9ANPC1MAPTLMNA | |
| SCHEMBL21463824 | 0.77 | MAPK1 (0.52) | SMN1; SMN2RAB9ANPC1MAPTKDM4E | |
| SCHEMBL30615324 | 0.77 | MAPK1 (0.52) | SMN1; SMN2RAB9ANPC1MAPTKDM4E | |
| SCHEMBL29581611 | 0.75 | MAPK14 (0.56) | SMN1; SMN2RAB9ANPC1MAPTKDM4E | |
| SCHEMBL29118425 | 0.72 | NPC1 (0.60) | SMN1; SMN2RAB9ANPC1ALDH1A1LMNA | |
| SCHEMBL29118421 | 0.72 | SMN1; SMN2 (0.47) | SMN1; SMN2RAB9ANPC1MAPTHPGD | |
| SCHEMBL9847731 | 0.72 | MAPK14 (0.67) | SMN1; SMN2NPC1MAPTKDM4ETP53 | |
| SCHEMBL24156151 | 0.72 | MAPK14 (0.48) | SMN1; SMN2RAB9ANPC1MAPK14TGFBR1 | |
| SCHEMBL116288 | 0.71 | DYRK1A (0.58) | SMN1; SMN2RAB9ANPC1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| EP-3774739-B1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC (JP) | 2022-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | SMN1; SMN2 4287/4885RAB9A 2868/4885NPC1 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.